It indicated that CD16+ NK cells that infiltrated tumor lesions could recognize CD276+ tumor cells but with no capability of cytotoxicity before the treatment of PD-1 inhibitors, while it can kill CD276+ tumor cells after the treatment of PD-1 inhibitors. The gene discussed is FCGR3A; the disease is neoplasm.